OBJECTIVES: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a novel class of drugs to treat patients with Type 2 Diabetes Mellitus (T2DM). The attributes of the SGLT2i differ from those of other medications. Therefore, patients’ preferences for each of these attributes are of potential interest to patients, physicians, and payers. METHODS: A discrete choice experiment was conducted with patients with T2DM from the United Kingdom to examine 7 attributes of T2DM medications: efficacy (defined as reduction in blood glucose levels), urinary tract infection/genital infection side-effects, weight change, gastrointestinal/nausea side-effects, hypoglycemic events, blood pressure, and cardiovascular risk. Patients were presented with 20 total choices between 2 hypothetical T2DM medications each described by varying levels of the 7 attributes. Partial utilities were estimated using random effects multi-logit models, and relative importance (RI) values were calculated for each of the attributes. Data were analyzed for the overall sample, and by medication and gender subgroups. RESULTS: One hundred patients with T2DM completed the study (51% male; mean age=62.9, SD=11.1 years; mean BMI=32.7, SD=6.5; 50.0% taking 2+ T2DM medications). The four most important attributes to patients were: risk of hypoglycaemic events (relative importance (RI) = 24.7%), weight change associated with the medication (RI=20.6%), risk of gastrointestinal/nausea side-effects (RI=18.6%), and efficacy (RI=18.0%). The remaining attributes were of lesser importance: risk of urinary tract infection/genital infection side-effects (RI=9.9%), cardiovascular risk (RI=4.3%), and blood pressure changes (RI=3.9%). Additional results for subgroup analyses will be presented. CONCLUSIONS: Patients with T2DM consider the risk of hypoglycaemic events, weight changes associated with a medication, the risk of gastrointestinal/nausea side-effects, and the efficacy of a medication to be attributes of approximately equivalent importance for T2DM medications. Prescribing physicians should consider these characteristics of medications as they may contribute to patients’ overall satisfaction with their diabetes therapy.